Atrial fibrillation: current therapeutic approaches.

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Atrial fibrillation (AF) poses a significant risk of life-threatening strokes.
• Anticoagulation therapy, including warfarin or aspirin, is crucial for managing embolic events in chronic AF patients with underlying heart conditions.
• Mitral valve stenosis is a common comorbidity associated with atrial fibrillation.

Purpose of the Study:

• To review the role of anticoagulation in atrial fibrillation management.
• To outline the timing and duration of anticoagulation therapy relative to cardioversion.
• To discuss current strategies for cardioversion in atrial fibrillation.

Main Methods:

• Literature review of anticoagulation and cardioversion strategies for atrial fibrillation.
• Analysis of treatment protocols for acute versus chronic atrial fibrillation.
• Evaluation of pharmacological (quinidine) and electrical cardioversion efficacy.

Main Results:

• Anticoagulation is recommended for chronic atrial fibrillation, starting three weeks before and continuing four weeks after cardioversion.
• Anticoagulation is generally not required before cardioversion in acute atrial fibrillation.
• Quinidine is a primary agent for medical cardioversion in stable patients; electrical cardioversion is effective for unstable patients or when drug therapy fails.
• Long-term antiarrhythmic therapy, such as quinidine, may be necessary to maintain sinus rhythm.

Conclusions:

• Anticoagulation management is critical for stroke prevention in atrial fibrillation patients undergoing cardioversion.
• Cardioversion strategies should be tailored based on the acuity of atrial fibrillation and patient stability.
• Maintaining sinus rhythm post-cardioversion often requires ongoing antiarrhythmic medication.